TGR-1202 (PI3K-delta inhibitor) + Ruxolitinib combination
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-05-19 — TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea: Phase 1 open-label trial (trial-early) evaluating TGR-1202 (umbralisib, PI3Kδ inhibitor) + ruxolitinib across PMF, PPV-MF, PET-MF, MDS/MPN, and hydroxyurea-resistant PV — first-in-combination test of dual JAK-STAT + PI3K-AKT blockade with this agent in MPNs. (novelty: 3)
Open questions
Related
Contributing findings
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
19-may-2026
novelty 3
per-area 3
introduces